XPhyto Therapeutics: Catching the Next Wave of Investment Opportunity in Cannabis

Pursuing cannabis opportunities in Germany

XPhyto was created to bridge the gap between traditional cannabis-based medicine and modern scientific approaches to therapeutic validations. They are a science-based cannabis company focused on formulation, clinical validation, and emerging European markets.

Moreover, XPhyto’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence. This is for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM).

XPhyto also acquired 100% of Vektor Pharma TF GmbH. This is a German narcotics manufacturer, importer and researcher. They have expertise in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips for the clinical management of pain.

Further, the company is pursuing additional opportunities in Germany including commercial cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.

“In the long term, its drug development, in the short term, its the import and distribution of cannabis products in Germany”, says CEO and Director, Hugh Rogers.

For more information on XPhyto Therapeutics Corp. (XPHY:CSE) please fill out the form below.

Request Investor Info